Dr. Öğr. Üyesi ERHAN APTULLAHOĞLU

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler 11

1. Brigimadlin (BI-907828) and napabucasin (BBI608) cooperatively trigger apoptosis in chronic lymphocytic leukemia cells by simultaneous iİnhibition of MDM2 and STAT3

APTULLAHOĞLU E.

Molecular Biology Reports , cilt.52, sa.1, 2025 (SCI-Expanded)

2. Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia

Aptullahoğlu E., Kaygusuz E.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , cilt.26, sa.17, ss.1-25, 2025 (SCI-Expanded)

3. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia

Aptullahoglu E., Howladar M., Wallis J. P., Marr H., Marshall S., Irving J., et al.

CANCERS , cilt.17, sa.2, ss.1-17, 2025 (SCI-Expanded)

4. Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.

Gungordu S., Aptullahoglu E.

Investigational new drugs , 2024 (SCI-Expanded)

5. RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia

APTULLAHOĞLU E., Nakjang S., Wallis J. P., Marr H., Marshall S., Willmore E., et al.

Biomedicines , cilt.12, sa.7, 2024 (SCI-Expanded)

6. SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.

Aptullahoglu E., Wallis J. P., Marr H., Marshall S., Bown N., Willmore E., et al.

International journal of molecular sciences , cilt.24, sa.14, 2023 (SCI-Expanded)

7. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

Aptullahoglu E., Ciardullo C., Wallis J. P., Marr H., Marshall S., Bown N., et al.

International Journal of Molecular Sciences , cilt.24, sa.3, 2023 (SCI-Expanded)

8. p53 as a biomarker and potential target in gastrointestinal stromal tumors

Wu C., Chen C., Huang W., Pan Y., APTULLAHOĞLU E., Yeh C., et al.

Frontiers in Oncology , cilt.12, 2022 (SCI-Expanded)

9. In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology

Sozer S., Aptullahoglu E., Shivarov V., Yavuz A. S.

International Journal of Laboratory Hematology , cilt.41, sa.4, 2019 (SCI-Expanded)

10. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

Ciardullo C., Aptullahoglu E., Woodhouse L., Lin W., Wallis J. P., Marr H., et al.

Haematologica , cilt.104, sa.12, ss.2429-2442, 2019 (SCI-Expanded)

11. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

Wu C., Esfandiari A., Ho Y., Wang N., Mahdi A. K., Aptullahoglu E., et al.

British Journal of Cancer , cilt.118, sa.4, ss.495-508, 2018 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler 2

1. Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme

APTULLAHOĞLU E.

Osmaniye Korkut Ata Üniversitesi Fen Bilimleri Enstitüsü Dergisi (Online) , cilt.8, sa.4, 2025 (Hakemli Dergi)

2. Preclinical Evaluation of Brigimadlin (BI 907828) As a Novel MDM2 Inhibitor in Acute Lymphoblastic Leukemia

APTULLAHOĞLU E.

Black Sea Journal of Engineering and Science , cilt.8, sa.5, ss.1450-1459, 2025 (Hakemli Dergi)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 13

1. Kronik Lenfositik Lösemide Sinerjistik İlaç Etkileşimlerinin Nicel Değerlendirilmesine Yönelik ZIP Sinerji Skorlama ve Chou-Talalay Modellerinin Yöntemsel Karşılaştırması

APTULLAHOĞLU E.

26. ULUSAL BİYOLOJİ KONGRESİ (UBİKON 2025), 03 Eylül 2025, (Özet Bildiri)

2. Identification Of Key Predictive Biomarkers For mTOR Inhibitor Response In Leukemia Cell Lines Using Multi-Omics Database Mining And Statistical Modeling

APTULLAHOĞLU E.

6th International Congress of Applied Statistics (UYİK 2025), 14 Mayıs 2025, (Özet Bildiri)

3. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with the MDM2-p53 antagonist idasanutlin in acute lymphoblastic leukaemia

APTULLAHOĞLU E.

EACR2023, Torino, İtalya, 11 - 14 Haziran 2023, (Özet Bildiri)

4. Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells

Willmore E., APTULLAHOĞLU E., Zhao Y., Kyle S., Thomas H., Ahn M., et al.

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 Eylül 2019, (Özet Bildiri)

5. The spliceosome inhibitor E7107 induces a dose-dependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes

APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Edinburgh, Saint Helena, 20 - 23 Eylül 2019, (Özet Bildiri)

6. E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes

APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., Willmore E., Lunec J.

The 25th Biennial Congress of the European Association for Cancer Research (EACR25), Amsterdam, Hollanda, 30 Haziran - 03 Temmuz 2018, (Özet Bildiri)

7. Combined drug targeting of p53 negative regulation in cutaneous melanoma

APTULLAHOĞLU E.

Workshop On Rare Diseases, İstanbul, Türkiye, 03 Aralık 2022, (Özet Bildiri)

8. Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells

Wu C., Esfandiari A., Ho Y., Shepherd C., Mahdi A. K., APTULLAHOĞLU E., et al.

(AACR) 2017 Annual Meeting, Washington, Kiribati, 1 - 05 Nisan 2017, (Özet Bildiri)

9. Activation of p53 by the MDM2 Antagonist RG7388 in CLL Cells:Analysis of ExVivo Signalling, Cell Death and Gene Signature

Willmore E., Ciardullo C., APTULLAHOĞLU E., Woodhouse L., Wallis J. P., Marr H., et al.

The biennial International Workshop on Chronic Lymphocytic Leukemia, New York, Amerika Birleşik Devletleri, 12 - 15 Mayıs 2017, (Özet Bildiri)

10. The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia

Ciardullo C., Woodhouse L., APTULLAHOĞLU E., Wallis J. P., Marr H., Marshall S., et al.

58th ASH Annual Meeting Exposition, San Diego, 3 - 06 Aralık 2016, cilt.128, ss.893, (Özet Bildiri)

Kitaplar 2

1. Technical English for Bioengineering Students

APTULLAHOĞLU E.

Cinius Yayınları, İstanbul, 2022

2. Professional English for Molecular Biology Students

APTULLAHOĞLU E.

Cinius Yayınları, 2021

Dr. Öğr. Üyesi ERHAN APTULLAHOĞLU

Yayınlar & Eserler

1. Brigimadlin (BI-907828) and napabucasin (BBI608) cooperatively trigger apoptosis in chronic lymphocytic leukemia cells by simultaneous iİnhibition of MDM2 and STAT3

2. Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia

3. Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia

4. Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.

5. RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia

6. SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.

7. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

8. p53 as a biomarker and potential target in gastrointestinal stromal tumors

9. In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology

10. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells

11. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

1. Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme

2. Preclinical Evaluation of Brigimadlin (BI 907828) As a Novel MDM2 Inhibitor in Acute Lymphoblastic Leukemia

1. Kronik Lenfositik Lösemide Sinerjistik İlaç Etkileşimlerinin Nicel Değerlendirilmesine Yönelik ZIP Sinerji Skorlama ve Chou-Talalay Modellerinin Yöntemsel Karşılaştırması

2. Identification Of Key Predictive Biomarkers For mTOR Inhibitor Response In Leukemia Cell Lines Using Multi-Omics Database Mining And Statistical Modeling

3. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with the MDM2-p53 antagonist idasanutlin in acute lymphoblastic leukaemia

4. Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells

5. The spliceosome inhibitor E7107 induces a dose-dependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes

6. E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes

7. Combined drug targeting of p53 negative regulation in cutaneous melanoma

8. Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells

9. Activation of p53 by the MDM2 Antagonist RG7388 in CLL Cells:Analysis of ExVivo Signalling, Cell Death and Gene Signature

10. The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia

11. Evaluating the effect of RG7388 and HDM201 as single agents in a panel of B-cell lines and CLL samples

12. Mineralogical and petrographical properties of the volcanic activities in the Sakarya Continent Turkey

13. In-Cell Detection By Flow Cytometry of JAK2 V617F Mutation Using Gold Nanoflares

1. Technical English for Bioengineering Students

2. Professional English for Molecular Biology Students